Module 4.2.2 — Pharmacokinetic Study Reports — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 4.2.2 — the nonclinical pharmacokinetic study reports (absorption, distribution, metabolism, excretion, and toxicokinetics).
Why it exists. Animal PK/ADME establishes how the drug is handled by the body and links the doses used in toxicology to drug exposure, so human starting doses and safety margins can be set.
How it is produced here. No real animal studies were run for this portfolio, so this is deep-knowledge mock: the study designs, endpoints, and conclusions are realistic domain content standing in for real laboratory data.
Format & governing standard. ICH M4S; M3(R2); S3A; GLP (toxicokinetics)
Module 4.2.2 — Pharmacokinetic Study Reports — GLPI-103
| Field | Value |
|---|---|
| Document ID | M4-2.2 |
| Version | 2.0 (expanded) |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Standard | ICH M4S; M3(R2); S3A; GLP (toxicokinetics) |
| Confidentiality | Confidential |
[MOCK — deep-knowledge assumption]Nonclinical PK/ADME study reports; data illustrative but technically representative of a C18-diacid-acylated, albumin-binding peptide.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Nonclinical / DMPK | Initial reports |
| 2.0 | 2026-06-30 | Nonclinical / DMPK | Expanded — cross-species PK parameters, albumin-binding half-life mechanism, metabolism/excretion, human projection |
4.2.2.1 Analytical Methods
Validated LC-MS/MS for GLPI-103 in plasma across species (selectivity, calibration range, accuracy/precision, dilution linearity, matrix and freeze-thaw stability), with an orthogonal ligand-binding assay for cross-validation; a tiered anti-drug-antibody (ADA) assay (screen → confirm → titre, with a neutralising-antibody assay) supports immunogenicity. [MOCK]
4.2.2.2 Absorption — Report PK-ADME-01 (non-GLP) + integrated GLP toxicokinetics
Mechanistic basis: the C18 fatty-diacid acylation drives strong, reversible binding to serum albumin (>99%), which (with the Aib protease-resistance substitutions) gives low clearance and a long half-life — the molecular basis for once-weekly IV dosing. Oral absorption is enabled transiently by the SNAC permeation enhancer.
Parameter (single dose) [MOCK] | Rat | Monkey | Human (projected) |
|---|---|---|---|
| Clearance (CL) | low | low | ~0.04 L/h |
| Volume of distribution (Vss) | ~0.1 L/kg | ~0.08 L/kg | ~7–10 L |
| Terminal half-life (t½) | 24–48 h | 60–90 h | ~5–7 days |
| Plasma protein binding | >99% | >99% | >99% |
| Oral bioavailability (with SNAC) | — | ~1–2% | ~1% (basis for 8 mg oral vs 4 mg IV) |
| Dose proportionality | linear | linear | linear (Phase 1) |
Toxicokinetics integrated into the GLP repeat-dose studies (TOX-RD-01/02; M4-2.3) showed approximately dose-proportional AUC, minimal accumulation (~1.3×), and no relevant sex difference; these data define the exposure margins in M4-2.3.
4.2.2.3 Distribution
Low volume of distribution consistent with confinement to plasma and extracellular fluid by high albumin binding; tissue distribution (quantitative whole-body autoradiography, rat) consistent with a peptide with no unexpected accumulation; placental transfer low.
4.2.2.4 Metabolism
GLPI-103 is metabolised by proteolytic catabolism (endopeptidases and neprilysin) to small peptide fragments and amino acids, with β-oxidation and ω-oxidation of the fatty-diacid side chain; the Aib²/Aib¹³ substitutions confer resistance to DPP-4. No meaningful cytochrome-P450 metabolism was observed. No human-specific or disproportionate metabolites were identified (MIST not triggered).
4.2.2.5 Excretion
Elimination is predominantly via catabolism; intact GLPI-103 is a minor component of urinary/biliary excretion. Metabolite-related material is recovered in urine and faeces.
4.2.2.6 Pharmacokinetic Drug Interactions
Low metabolic drug-interaction potential: not a substrate/inhibitor/inducer of major CYP enzymes or principal transporters at clinically relevant concentrations; no relevant interaction with metformin. As a high-albumin-binder, displacement interactions were assessed and judged not clinically meaningful. [MOCK]
4.2.2.7 Immunogenicity
Anti-drug antibodies were low-titre and non-neutralising, without meaningful impact on PK, PD, or safety in repeat-dose studies — consistent with a largely human-sequence peptide.
Conclusion
The nonclinical DMPK profile — albumin-binding-driven low clearance and long half-life, proteolytic (non-CYP) metabolism, low drug-interaction potential, and SNAC-enabled oral absorption — supports the once-weekly IV and once-daily oral clinical regimens and underpins the exposure-margin and human-dose projections (M2.4; M2.7.2).
Comments (0)
No comments yet. Be the first to say something!